Title |
Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses
|
---|---|
Published in |
AIDS Research and Therapy, April 2006
|
DOI | 10.1186/1742-6405-3-9 |
Pubmed ID | |
Authors |
Patricia Cornejo-Juárez, Patricia Volkow-Fernández, Kenia Escobedo-López, Diana Vilar-Compte, Guillermo Ruiz-Palacios, Luis Enrique Soto-Ramírez |
Abstract |
Co-infection with hepatitis B virus (HBV) and human immunodeficiency virus (HIV) is not infrequent as both share same route of exposure. The risk of developing chronic hepatitis B virus is 6%, in general population but can reach 10-20% in HBV/HIV co-infected patients. When compared to general population, the response rate to HBV vaccine in HIV-infected patients is diminished, so previous studies have tried to improve this response using variety of schedules, doses and co-administration of immunomodulators. The purpose of this study was to evaluate two doses of recombinant HBV vaccine (10 or 40 microg), IM at 0, 1 and 6 months. Vaccination response was measured 30-50 days after last dose; titers of >9.9 IU/L were considered positive. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 4% |
Unknown | 23 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 6 | 25% |
Researcher | 4 | 17% |
Student > Ph. D. Student | 3 | 13% |
Student > Bachelor | 2 | 8% |
Professor | 2 | 8% |
Other | 5 | 21% |
Unknown | 2 | 8% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 14 | 58% |
Biochemistry, Genetics and Molecular Biology | 2 | 8% |
Immunology and Microbiology | 2 | 8% |
Agricultural and Biological Sciences | 1 | 4% |
Decision Sciences | 1 | 4% |
Other | 1 | 4% |
Unknown | 3 | 13% |